A Phase 3, Open-Label, Randomized Study of Perioperative Dostarlimab Monotherapy Versus Standard of Care in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
This study tests whether an immunotherapy drug called dostarlimab, given on its own before and after surgery, works better than standard care for colon cancer that is dMMR or MSI-high (tumors that cannot repair certain DNA copying errors). In this study, standard care means surgery right away, followed by chemotherapy (FOLFOX or CAPEOX) or close monitoring, as your doctor recommends. People in the dostarlimab group do not receive chemotherapy.
You may be able to join if you are 18 or older and have been newly diagnosed with colon cancer that can be removed by surgery, is stage III or T4N0 on scans, and is dMMR or MSI-high on tumor testing done before surgery. You must not have had any surgery, chemotherapy, immunotherapy, radiation or other treatment for this cancer yet, and you need to be able to carry out your daily activities (ECOG 0–1). People whose cancer has spread to distant organs, who need urgent surgery for a blocked bowel, or who have certain conditions such as active autoimmune disease, interstitial lung disease or pneumonitis, cirrhosis, or a prior organ or stem-cell transplant cannot take part.
Participants are assigned by chance: 2 out of 3 receive dostarlimab and 1 out of 3 receive standard care. In the dostarlimab group, you receive dostarlimab by IV every 3 weeks for 4 doses, then have surgery, then receive dostarlimab every 6 weeks for 6 more doses, without chemotherapy. In the standard-care group, you have surgery first, followed by FOLFOX or CAPEOX chemotherapy for about 3 to 6 months or close monitoring, as your doctor recommends. Your care team will check your health with regular visits, scans and tests.
The study is recruiting at 27 locations in the United States (Arizona, California, Connecticut, Illinois, Kansas, Maryland, Michigan, Minnesota, Nebraska, New York, North Carolina, Ohio, South Dakota, Virginia and Wisconsin) and 4 in Canada (Halifax, Ottawa, Toronto and Montreal), among sites in 27 countries. The registry listing was last updated in January 2026, so contact the study team to confirm which sites are open.
- 1Tests dostarlimab alone, before and after surgery, against standard care (surgery, then chemotherapy or monitoring).
- 2For newly diagnosed, untreated stage III or T4N0 dMMR/MSI-high colon cancer that can be removed by surgery.
- 3Recruiting at 27 U.S. and 4 Canadian sites, among sites in 27 countries.
Related video
Related links
Outside pages about this study, checked by our team
This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.